Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 5/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30214468 | 1.00 | FFAR1 (0.58) | FFAR1GRM5APPGRM4KCNH2 | |
| Hydrochloric Acid SCHEMBL19668206 | 0.98 | FFAR1 (0.57) | FFAR1GRM5APPGRM4KCNH2 | |
| SCHEMBL27965841 | 0.90 | FFAR1 (0.55) | FFAR1GRM5GRM4KCNH2 | |
| SCHEMBL352291 | 0.88 | GRM5 (0.65) | GRM5KCNH2CYP1A2 | |
| SCHEMBL31673060 | 0.87 | GRM5 (0.55) | FFAR1GRM5KCNH2CYP1A2 | |
| SCHEMBL7873393 | 0.84 | FFAR1 (0.49) | FFAR1GRM5KCNH2CYP1A2 | |
| SCHEMBL14061855 | 0.84 | GRM5 (0.53) | FFAR1GRM5KCNH2 | |
| SCHEMBL5569770 | 0.84 | GRM5 (0.53) | FFAR1GRM5KCNH2CYP1A2 | |
| SCHEMBL28950042 | 0.84 | GRM5 (0.56) | FFAR1GRM5KCNH2 | |
| SCHEMBL4750207 | 0.84 | FFAR1 (0.53) | FFAR1GRM5KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108794385-B | Method for synthesizing phenylethynyl pyridine derivative | 陕西师范大学 | 2021-09-21 | — | — | CN | claimed |
| CN-108794385-A | A method of synthesis phenylethynylpyridin derivative | 陕西师范大学 | 2018-11-13 | — | — | CN | claimed |
| EP-1294699-B1 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORP (US) | 2016-04-13 | — | — | EP | claimed |
| US-7432403-B2 | Cyclic palladium compounds having coordinated thereto bis (diphenylphosphine) ferrocene ligands which inhibit the activity of proteins and enzymes and treatment of diseases and disorders associated therewith | Fundação De Amparo À Pesquisa Do Estado de São Paulo (BR) | 2008-10-07 | — | — | US | claimed |
| US-20060106100-A1 | Cyclic palladium compounds having coordinated thereto bis (diphenylphosphine) ferrocene ligands which inhibit the activity of proteins and enzymes and treatment of diseases and disorders associated therewith | FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAULO (BR) | 2006-05-18 | — | — | US | claimed |
| CN-120463640-A | Method for preparing diaryl acetylene and phenylethynyl pyridine photocycloaddition product | 北京化工大学 | 2025-08-12 | — | — | CN | disclosed |
| CN-120463640-A | Method for preparing diaryl acetylene and phenylethynyl pyridine photocycloaddition product | 北京化工大学 | 2025-08-12 | — | — | CN | disclosed |
| CN-118290328-A | Hydrocarbon pyridine and preparation method thereof | 北京师范大学 | 2024-07-05 | — | — | CN | disclosed |
| US-11993618-B2 | Water soluble mono-branched and di-branched complexing agents, and corresponding lanthanide complexes | CISBIO BIOASSAYS (FR) | 2024-05-28 | — | — | US | disclosed |
| EP-4366739-A1 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2024-05-15 | — | — | EP | disclosed |
| EP-2945957-B1 | NOVEL WATER-SOLUBLE COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES | CISBIO BIOASSAYS (FR) | 2023-11-08 | — | — | EP | disclosed |
| CN-110914259-B | Novel water-soluble mono-and di-branched complexing agents and corresponding lanthanide complexes | CISBIO生物试验公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2005104836-A2 | DROSOPHILA MODELS FOR DISEASES AFFECTING LEARNING AND MEMORY | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005056719-A1 | ORGANIC ELEMENT FOR ELECTROLUMINESCENT DEVICES | EASTMAN KODAK COMPANY (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050123795-A1 | Having a phosphorescent light emitting layer containing an organometallic complex with Iridium, Rhodium, Osmium, Platinumt, or Palladium and a fused pyrazole or imidazole compound | GLOBAL OLED TECHNOLOGY LLC | 2005-06-09 | — | — | US | disclosed |
| US-6686345-B2 | INCLUDES AN AZA-ENEDIYNE, AZA-ENYNE ALLENE, OR AN AZA-DIALLENE; ARE PREFERABLY NON-HYDROLYZABLE, CATIONIC COMPOUNDS THAT BIND TO NUCLEIC ACIDS. | RESEARCH DEVELOPMENT FOUNDATION | 2004-02-03 | — | — | US | disclosed |
| US-20020132797-A1 | DNA-cleaving antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-19 | — | — | US | disclosed |
| US-5886240-A | Process for preparing aromatic acetylenes using palladacycles as catalysts | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-03-23 | — | — | US | disclosed |
| US-5457186-A | Immunoassay | WALLAC OY (FI) | 1995-10-10 | — | — | US | disclosed |
| EP-0649020-A1 | Luminescent lanthanide chelates with decreased non-radiative energy loss | WALLAC OY (FI) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993618-B2 | Water soluble mono-branched and di-branched complexing agents, and corresponding lanthanide complexes | LASP1, RCC1, LGALS1 | FFAR1 2635/4885GRM5 4165/4885APP 4206/4885 |
| US-20060106100-A1 | Cyclic palladium compounds having coordinated thereto bis (diphenylphosphine) ferrocene ligands which inhibit the activity of proteins and enzymes and treatment of diseases and disorders associated therewith | PREP, DNPEP, RNASE1 | FFAR1 4769/4885GRM5 3562/4885APP 1768/4885 |
| US-20020132797-A1 | DNA-cleaving antitumor agents | DNASE1, DNASE1L3, DCLRE1B | FFAR1 4220/4885GRM5 3972/4885APP 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.